Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive

In brief

Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.

Key facts

Study ID
NCT00157339
Run by
Eli Lilly and Company
People needed
299
Starts
2005-08-01
Expected to finish
2008-05-01
Last updated by the study team
2019-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.